Murat Terzi

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

Sean J. Pittock, Achim Berthele, Kazuo Fujihara et al. · New England Journal of Medicine · 2019 · 797 citations · Full text

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

J William L Brown, Alasdair Coles, Dana Horáková et al. · JAMA · 2019 · 511 citations · Full text

Defining reliable disability outcomes in multiple sclerosis

Tomáš Kalinčík, Gary Cutter, Tim Spelman et al. · Brain · 2015 · 223 citations · Full text